SCHEMBL10134928

SCHEMBL10134928

N#Cc1ccc2c(c1)nc(NCCn1ccnc1)c1ccsc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 11/20 0.45
CSNK2A2 P19784 1/20 0.42
CSNK2B P67870 1/20 0.42
SOD1 P00441 2/20 0.41
TBXAS1 P24557 2/20 0.40
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
CASP1 P29466 1/20 0.39
CLK1 P49759 1/20 0.39
CASP7 P55210 1/20 0.39
HSD17B10 Q99714 1/20 0.39
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
CYP19A1 P11511 1/20 0.38
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10134913 0.88 CSNK2A1 (0.48) CSNK2A1CSNK2A2CSNK2BALDH1A1
SCHEMBL13688012 0.85 CSNK2A1 (0.47) CSNK2A1CSNK2A2CSNK2BSOD1TBXAS1
SCHEMBL10134927 0.82 CSNK2A1 (0.44) CSNK2A1CSNK2A2CSNK2BALDH1A1
SCHEMBL10134909 0.81 CSNK2A1 (0.67) CSNK2A1CSNK2A2CSNK2BALDH1A1KDM4E
SCHEMBL10134902 0.80 CSNK2A1 (0.65) CSNK2A1CSNK2A2CSNK2B
SCHEMBL10134896 0.78 CSNK2A1 (0.69) CSNK2A1CSNK2A2CSNK2BALDH1A1KDM4E
SCHEMBL10135002 0.78 CSNK2A1 (0.52) CSNK2A1CSNK2A2CSNK2B
SCHEMBL10168737 0.78 CSNK2A1 (0.48) CSNK2A1CSNK2A2CSNK2BALDH1A1
SCHEMBL10135018 0.77 CSNK2A1 (0.47) CSNK2A1CSNK2A2CSNK2B
SCHEMBL10135014 0.77 CSNK2A1 (0.47) CSNK2A1CSNK2A2CSNK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 CSNK2A1 680/4885CSNK2A2 810/4885CSNK2B 772/4885
US-20090239859-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 CSNK2A1 680/4885CSNK2A2 810/4885CSNK2B 772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.